Riyadh Set to Become the Arab World’s First Digital Capital in 2020
Riyadh is set to become the Arab world’s first ever digital capital city. The announcement was revealed at the 23rd session of the Council of Arab Ministers of Communications and Information Technology, which took place on December 18 at The Ritz-Carlton hotel in Saudi Arabia’s capital.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191219005518/en/
Minister of Communications and Information Technology His Excellency Eng. Abdullah Al-Swaha (Photo: AETOSWire)
The decision to name Riyadh the Arab Digital Capital follows the city’s prominent role in adopting and promoting the use of digital technologies to enhance socio-economic development, advance healthcare, improve education, and to ultimately increase community welfare, which helped to elevate the ICT sector's contribution to GDP to 4%. The Kingdom also climbed 16 places in World Economic Forum’s Global Competitive Index 2019 in terms of ICT adoption, and topped in the ease of doing business ranking according to the World Bank’s 2020 report.
The ‘Arab Digital Capital’ initiative seeks to encourage the creation of a stimulating ecosystem for investment in Information and Communications Technology (ICT), activate initiatives that develop knowledge within the ICT industry across Arab countries, and to adopt new initiatives that facilitate and enhance tech entrepreneurship in the Arab region.
Minister of Communications and Information Technology His Excellency Eng. Abdullah Al-Swaha extended congratulations to the Custodian of the Two Holy Mosques King Salman bin Abdulaziz Al Saud, and to His Royal Highness Prince Muhammad bin Salman bin Abdulaziz, Crown Prince and Deputy Prime Minister and Minister of Defense. He hailed the great and unlimited support to the sector by the Kingdom’s good government, which highlighted it regionally and internationally. He also emphasized the acknowledgment as an addition added to the record of the Saudi ICT sector’s march, which has advanced the country’s digital infrastructure making it eligible for obtaining this title and precedence. This came in a keynote speech at the announcement ceremony attended by the Secretary-General of International Telecommunication Union, relevant Ministers, Arab Ambassadors to Riyadh and a number of interested ICT professionals and specialists.
Saudi Arabia is the region’s largest ICT market and ranks 13th globally, with a value of $28.7 billion in 2019 and strong growth in both the consumer and enterprise segments. Supported by a young and tech-savvy population, Saudi Arabia is a market of early technology adopters, with one of the highest social media penetrations in the world. Mobile subscribers stood at 43.8 million in 2019, representing a 129% penetration of the total population.
Following the launch of Vision 2030, the last few years have seen a significant acceleration in the proliferation of digital transformation initiatives. In 2019, Saudi Arabia was second among G20 countries for radio spectrum liberalization, with a subsequent positive impact on the quality of digital services provided by local operators experienced.
Supported by a 93% internet user penetration versus the global average of 53%, Saudi Arabia also became the first adopter of commercial 5G technology in the Middle East and North Africa, and the third largest globally – an achievement that is set to boost the adoption of other digitalization trends characterizing the Fourth Industrial Revolution. In parallel, the Kingdom is the 5th G20 country in internet speed, and jumped 91 places from 105th to 14th in the relevant global rankings, with a 51.8Mbps average speed.
Earlier this year, Ministry of Communications and Information Technology (MCIT) launched a five-year strategy aimed at accelerating the sector’s growth by 50% and elevating its contribution to GDP by $13.3 billion. Despite the global trend towards job disruption as a consequence of digitalization, the MCIT’s technology localization initiatives have significantly increased the ICT sector’s employment capacity in 2019.
The “Arab Digital Capital” award is a recognition of Saudi Arabia’s achievements in the ICT sector and is set to provide an even greater impetus to the country’s already busy regional and international agenda in the coming year. As the only Arab nation represented in the G20, Saudi Arabia will be hosting the G20 meetings throughout 2020, under the theme “Realizing Opportunities of the 21st Century for All.” The G20 Leaders Summit will take place on November 20-21, 2020 in Riyadh, the newly nominated Digital Capital of the Arab World.
Editor’s Note: new website for Riyadh Arab Digital Capital 2020 is at www.adcapitals.org
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191219005518/en/
Contact information
The Communications and Information Technology Commission – Saudi Arabia
Saeed H. AlGhamdi
Office: +966 11 4618244
Email: Shghamdi@citc.gov.sa | www.citc.gov.sa
Twitter: @CITC_SA
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
